BluePrint Medicines KIT D816V BLU-SM-1101 Evalute the prevalence of the KIT D816V mutation i peripheral blood of patients with evidence of systemic mast cell activation

Administered By

Awarded By

Contributors

Start/End

  • February 9, 2022 - February 14, 2024